# MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

> **NCT00101179** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 63 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- de Novo Myelodysplastic Syndrome
- Leukemia
- Myelodysplastic Syndrome
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Entinostat

## Key facts

- **NCT ID:** NCT00101179
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11-03
- **Primary completion:** 2011-04-20
- **Final completion:** 2014-02-03
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2019-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00101179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00101179, "MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00101179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*